Investors

The hard work of building businesses is what drives returns for investors, but maximising value also means buying well and selling well. As your advisers, we can make a big difference to the outcome.

Our deep sector knowledge and long-established international network mean we can offer insights on industry trends, strategic positioning and competitive intelligence that give us an edge over generalist advisers. This specialism is allied to buy-side and sell-side M&A expertise across the full range of deal structures – from growth capital to minority stake sales, buy-outs and strategic exits.

Whether you are a venture capital provider, buyout fund, family office or infrastructure investor, we understand your objectives and have the capability to help you achieve them.

Crucially, we work together as one-team. We collaborate and work with partners, and our carefully nurtured internal culture permeates through the whole organisation. As Managing Partner, Julie Langley puts it, “For CG Results, every deal is important to everybody in our firm.”

Deals are incredibly complex and never straightforward, but we never give up once we are on board. 100 per cent of the deals we’ve closed are referenceable from our past clients.

Mark Williams

Managing Director

Services

We’ve been providing independent M&A and corporate finance advice and execution services to entrepreneurs, corporates and investors in the technology and healthcare sectors for over 30 years. Whether your aim is to realise value or to find a partner for future growth, we will be your guide.

M&A

When the time comes, we’re by your side every step of the way. We help you evaluate your market, find the right buyer, and deliver the true value of your business.

Divestments

With a strong track record in company carve-outs, we can help you realign your portfolio and redeploy capital to the growth of your core business.

Licensing

We support clients with in-licensing, out-licensing, drug licensing, and facility licensing and we understand the complexities that are unique to licensing deals.

Equity Fundraising

We understand that optimising terms is critical, but so is finding the right partner for growth. We help articulate your equity story, target the best investors and negotiate the right deal.

Strategic Advice

Having completed over 300 transactions, we bring the breadth of perspectives and depth of business experience to provide advice on strategic options for businesses.

Recent Deals

Nov 2022
has been acquired by
An Interlock Equity-backed company
Oct 2022
has been acquired by
A Trill Impact-backed company
Jul 2022
has received investment from
Jul 2022
has divested its API site in Rhode Island, USA, to
Jun 2022
A Kester Capital-backed company
has received investment from
Jun 2022
Has invested in
Jun 2022
has been acquired by
A company backed by GTCR and The Carlyle Group
May 2022
A subsidiary of Servier
has divested its anti-LAG-3 monoclonal antibody to
A subsidiary of Sino Biopharmaceutical Limited
Apr 2022
has received investment from
and EnBW New Ventures, with follow-on investment from ETF Partners
Apr 2022
has been acquired by
A company backed by TA Associates, HGGC, Charlesbank, Harvest Partners SCF

CG Results. Great people creating great outcomes, together.

Latest Insights

Insights
5th December 2022

The end of the ecommerce boom or the start of a new era of innovation and digital disruption?

Katherine Hobbs, Director at CG Results and Neil Trickett Managing Director of E2X discuss the outlook for ecommerce and why, despite the headlines, they see opportunities for operators and investors across the sector over the next 18-24 months As Black Friday and Cyber Monday draw to a close, you could be forgiven for concluding that […]

Reports
23rd November 2022

Pharma Licensing – an introduction

We are pleased to share our introduction to Pharma Licensing. This guide provides an overview of both in and out-licensing as well as insights on what to anticipate during the process. We hope that you find this guide useful and look forward to discussing the underlying themes with you. Do get in touch! Click to […]

Insights
17th October 2022

Pharma Licensing: the why the how and a few things to get right

Platform or asset licensing has increasingly been utilised across the bio-pharmaceutical industry to achieve Corporate objectives by sharing intellectual property (IP).  IP includes patents and know-how and third-party proprietary technologies, compounds and products, and can be used to build on existing therapeutic areas, expand into different geographies or to diversify portfolios.  A pharma licensing deal […]